MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

− Sub-analysis from Company’s Phase 3 SPOTLIGHT trial examined impact of POSLUMA on treatment plans for recurrence after curative-intent primary therapy – MONROE TOWNSHIP, N.J. & OXFORD, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

Please provide your email address to receive an email when new articles are posted on . All men with BRCA2 mutations treated with olaparib monotherapy achieved at least a 50% decline in PSA. The study ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

New data suggest that olaparib without ADT could be a reasonable treatment strategy in selected patients with high-risk prostate cancer that recurs after radical prostatectomy. Olaparib monotherapy ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...